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Epidemiological studies suggest unique occurrence patterns of Hodgkin lymphoma (HL) worldwide. In most Western countries
there is a clear bimodal age distribution with an early peak in young adults followed by a second peak in older adults, particularly
among males. In the Middle East and Asia, HL is more common in early childhood. There also are marked racial diﬀerences in the
presentations of HL and HL subtypes, and particular single nucleotide polymorphisms (SNPs) have been identiﬁed as etiological
factors suggesting that gene-gene and gene-environment interactions are involved. Personal health choices such as exercise and
smoking may modify an individual’s chances of developing HL. Numerous studies highlight the impact that exposure to Epstein-
Barr virus and other environmental factors have on HL risk. Understanding the relative importance of each of these ﬁndings and
theirlinkstoHLdevelopmentandsurvivalwillhelpclinicalresearchersexpandcurativetherapiesandcreatepreventativestrategies
for HL.
1.Introduction
Hodgkin lymphoma is a cancer of the lymphatic system
commonly characterized by the presence of large, malignant
lymphoid cells, Reed-Sternberg cells. HL spreads predictably
and contiguously between lymph node groups [1], except
for in HIV-positive cases [2] and can be divided into
two categories, classic HL (CHL) and nodular lymphocyte
predominant(NLP)HL.CHLisfurtherdividedintonodular
sclerosis (NS), mixed cellularity (MC), lymphocyte-rich
(LR), and lymphocyte-depleted (LD) histologic subtypes. In
the United States (US), an estimated 8,490 new cases will
be diagnosed with HL while HL will be accountable for
1.320 deaths in 2010 [3]. The incidence rates for HL have
decreased slightly in men (0.6% per year), but increased
slightly in women (0.4% per year) over the past 30 years
[3]. According to data from the 2003–2007 Surveillance
Epidemiology and End Results (SEER) 17 registries, the
incidence rate for HL in US men and women is 2.8 per
100,000 people per year, with white Americans having
the highest incidence, followed blacks, Hispanics, and Asian
Americans [4]. Although HL can aﬀect children, especially
in developing nations, it commonly demonstrates a bimodal
distribution with peak incidence among adolescents/young
adults and among individuals over 55 years of age [5].
As noted above, HL is characterized by the presence of
Hodgkin and Reed-Sternberg (HRS) tumor cells, though
HRS cells only account for 0.1% to 10% of cells in tissue
[6]. HRS cells were determined to be derived from germinal
center B cells when researchers found clonally rearrange-
ments in both heavy and light chain immunoglobulin V
(IgV) genes, with somatic mutations present [7]. Before this
ﬁnding, though, the origin of HRS was highly speculative
because the cells rarely express typical B-cell markers such
as BCR, CD19, CD20, A-myb, and Syk—thus an HRS cell’s
immunophenotype is not reﬂective of its origin. In one
study of 238 cases (49% NS HL and 27% MC HL), after
staining tissue, only 13.8% of patients were CD20-positive.
Of those 33 cases, the majority were MC (57.5%) rather than
NS HL (36.3%) [8]. Though E12 and E47 (helix-loop-helix2 Advances in Hematology
transcription factors) are expressed in HRS as expected, the
function of these factors are compromised due to the strong
expression of their inhibitors, ID2 and ABF1 [9–11]. There
is also an absent or low expression of Pax5, the main B-cell
lineage commitment factor, in HRS cells [12]. Finally, Notch
1, a transcription factor that promotes T-cell development
and inhibits B-cell development of lymphoid precursors,
downregulates expression of E2A and EBF, induces ABF1,
and binds to Pax5 in HRS tumor cells. All these factors
contribute to the lost B-cell phenotype in HRS cells.
Treatment strategies for HL stratify patients into cate-
gories based upon prognostic factors, which include stage (as
classiﬁed by the Ann Arbor staging system or its Cotswold
modiﬁcation), age, anemia, and sedimentation rate [13].
The modern standard combination chemotherapy regimen
for HL is adriamycin, bleomycin, vinblastine, dacarbazine
(ABVD), which has usurped previous treatment strategies
such as radiation therapy alone and nitrogen mustard, vin-
cristine, procarbazine, prednisone (MOPP). Risk-adapted
therapy also may be utilized in which patients who have a
worse prognosis are given more aggressive treatment at the
outset [13]. In the 1960s, the 5-year survival rate for HL
was less than 10% [14]. Based on SEER 2003–2007 data,
the 5-year relative survival rates for white men and women
were 84% and 86%, respectively, while the rates for black
men and women were 78% and 86%, respectively [4]. Thus,
both HL incidence and survival rates are associated with
gender, race, and age. Despite the emerging data on the
origins of HRS cells, there are no preventative measures or
early interventions for HL. Only by studying this disease’s
epidemiologyandetiologycanwefurtherimprovetherapies,
methods for early detection, and prevention. In this paper,
we review the studies on epidemiology and the risk factors
for HL.
2. Patterns of HL Incidence across Populations
International population-based studies highlight regional,
racial,ethnic,andsocioeconomicdiﬀerencesintheincidence
ofHLaroundtheworld.Associationsbetweenclinicalsymp-
toms, features, and incidence of HL in a given population
could provide genetic and environmental insight into disease
etiology. Population-speciﬁc analyses of HL incidence in
Singapore, Israel, Canada, the United States Asian popula-
tion, and a multiethnic region of the United Kingdom oﬀer
insights into racial, ethnic, and socioeconomic variability in
the incidence and patterns of presentation for HL and HL
subtypes.
2.1. Singapore. As noted above, HL has been characterized
by a bimodal, age-speciﬁc, incidence pattern with a high
proportion of cases occurring in adolescents and young
adults, in Western industrialized countries [15]. In order to
analyze whether the young adult peak is associated with an
aﬄuent socioeconomic environment occurring as a byprod-
uct of growing up in industrialized countries, Hjalgrim et al.
evaluated HL incidence pattern in Singapore between 1968
and 2004, a period when Singapore experienced a major
socioeconomic shift towards Western lifestyle [16]. Using the
Singapore Cancer Registry, researchers identiﬁed a cohort
of 193 women and 337 men diagnosed with HL during the
study period. Among men, HL incidence rates increased
annually from 1968 to 2004 by 7% (95% Conﬁdence Interval
[CI] 3.4%–10.7%) and by 3.4% (95% CI 0.1%–6.8%) for
the 15 to 19 year-old and the 20 to 24 year-old age groups,
respectively. The trend was even more pronounced among
women in these age groups with increases of 13.7% (95%
CI 9.1%–18.6%) and 12.2% (95% CI 7.8%–10.8%), respec-
tively. Overall, however, the incidence peak for young adults
remained lower than that of young adults in the Western
world. Researchers speculate that birth cohort phenomenon
and ethnic genetic variation between Asians and non-Asians
may contribute to these diﬀerences.
2.2. Israel. Using data from the Israel Cancer Registry on
4,812HLcasesdiagnosedbetween1960and2005,Ariadetal.
found that the reported incidence level of HL in Israeli-born
youngadultJewsincreasedinrecentyearsandsurpassedthat
of any other western country [27]. To build on a previous
study that found a high incidence of Epstein-Barr virus
(EBV) expression in HL tumor cells in the Bedouin people,
Levy et al. examined HL cases in 4 community subgroups
in Southern Israel: Kibbutz residents (n = 11), Bedouin
(n = 19), new immigrants from the former USSR (n = 22),
and town-dwellers (n = 82) [28]. The study explored clinical
features, demographic data, stage at diagnosis, treatment
modality and outcome, and laboratory ﬁndings, and EBV
expression in each of the groups. Bedouin patients were
signiﬁcantly younger than the rest of the cohort when
diagnosed with HL, and the Bedouin group had a higher
proportion of males than any other group (79% versus
53%). Additionally, a greater proportion of Bedouin patients
presented with the MC HL subtype (P = .16), presented
with advanced disease (85.7%, P = .04), and were resistant
to treatment (47.4% versus 27.7%, P = .09) compared to
the other groups. EBV expression was signiﬁcantly more
frequent, and mdm-2 (murine double minute oncogene, a
negative regulator of the p53 tumor suppressor) was less
frequent in the Bedouin than in any other group [29].
However, interpreting the signiﬁcance of these diﬀerences is
diﬃcult given the small sample size of the study.
2.3. Canada. Pahwa et al. investigated the association
between ethnicity and incidence of HL in the Canadian
male population, taking into account medical history and
exposure to pesticides, to better understand both genetic
and environmental etiological factors [17]. Using a postal
questionnaire and telephone interview, they gathered infor-
mation from 316 Canadian men, over the age of 19,
diagnosed with HL between 1991 and 1994 and a random
sample of 1506 control subjects matched by age (±2y e a r s )
and gender. The authors deﬁned ethnicity as having 3 out
of 4 grandparents born in the same ethnic region, deﬁned
pesticide exposure based on a pilot study, and acquired
a medical history. When compared with people of North
American descent, people of Eastern European descent hadAdvances in Hematology 3
Table 1: Risk factors for Hodgkin lymphoma.
Risk Factor Odds Ratio 95% CI Study
Race/Ethnicity
E European versus N American descent 1.82 1.02–3.25 Pahwa [17]
Jewish versus Catholic 2.29 1.26–4.19 Chang [18]
Jewish versus Protestant 1.77 1.01–3.13 Chang [18]
Medical History
Measles 0.72 0.53–0.98 Pahwa [17]
0.7 0.53–0.94 Karunanayake [19]
Shingles 2.41 1.38–4.22 Pahwa [17]
2.16 1.31–3.56 Karunanayake [19]
Appendectomy 4.3 1.90–10.00 Cozen [20]
Acne 2.12 1.19–3.78 Pahwa [17]
Allergy desensitization shots 0.55 0.30–0.99 Pahwa [17]
Eczema 4.2 1.20–14.80 Cozen [20]
Family history of cancer (general) 1.93 1.40–2.65 Pahwa [17]
Family history of cancer (hematopoietic) 2.06 1.10–3.87 Chang [18]
Exposure History
Herbicide dichlorprop 6.35 1.56–25.92 Pahwa [17]
Ionizing radiation from Uranium 2.58 1.08–6.19 Karunanayake [19]
Ultraviolet radiation 0.62 0.40–0.96 Karunanayake [19]
Childhood environmental tobacco smoke (F 19–44 years) 1.7 0.90–3.40 Glaser [21]
Behaviors (thumb-sucking/putting things in mouth) resulting in
early oral exposure than twin
0.1 0.00–0.50 Cozen [20]
≥1 year nursery school attendance 0.64 0.45–0.92 Chang [18]
Physical Health
2X/wk physical activity (F 19–44 years) 0.58 0.39–0.87 Keegan [22]
2X/wk physical activity (F 45–79 years) 0.45 0.19–1.06 Keegan [22]
High BMI (F 19–44 years) 1.74 1.00–3.02 Keegan [22]
High BMI (F 45–79 years) 0.37 0.11–1.30 Keegan [22]
Low-dose aspirin use 0.6 0.30–1.00 Chang [23]
Smoking ≥10 lifetime packs of cigarettes 1.31 1.03–1.69 Chang [18]
Current smoker (M) 1.8 1.30–2.90 Briggs [24]
Molecular Biology
rs1585215 in NFKB1: AG versus AA 2.1 1.50–2.90 Chang [25]
rs1585215 in NFKB1: GG versus AA 3.5 2.20–5.70 Chang [25]
Carriership for −1237C (TLR9) 2.53 1.36–4.71 Mollaki [26]
Carriership for 2848A (TLR9) 6.20 1.30–28.8 Mollaki [26]
Socioeconomics
Having less than a high school education (15–54 years) 0.82 0.70–0.96 Chang [18]
E: East; N: North; F: female; M: male, BMI: body mass index.
a greater risk of HL (Odds Ratio adjusted [ORadj] 1.82,
95% CI 1.02–3.25, Table 1), while Asian descendants had
a signiﬁcantly lower risk (ORadj 0.17, 95% CI 0.02–1.33).
History of measles (ORadj 0.72, 95% CI 0.53–0.98) and
allergy desensitization shots (ORadj 0.55, 95% CI 0.30–
0.99) were negatively associated with HL incidence, whereas
acne (ORadj 2.12, 95% CI 1.19–3.78), shingles (ORadj
2.41, 95% CI 1.38–4.22), and a family history of cancer
(ORadj 1.93, 95% CI 1.40–2.65) were positively associated
with HL incidence in this cohort. Additionally, exposure to
the herbicide dichlorprop showed an increased risk of HL
(ORadj 6.35, 95% CI 1.56–25.92).
2.4. United States: Asian Population. Based on reports that
Asians have consistently low rates of HL incidence, Glaser
and Hsu explored individual genetic and environmental risk
factors in both US-born and foreign-born Asian populations
(Chinese, Japanese, Filipino, and Asian Indian) [30]. Glaser
and Hsu analyzed 225 US-born cases and 1,477 foreign-born4 Advances in Hematology
cases with data from the US SEER cancer registry, California
Cancer Registry, and the International Agency on Cancer
registry, all of which had preassigned ethnicity according
to their own standards. HL incidence rates were relatively
low for all Asians when compared to whites, but US-
born Asians had approximately double the incidence when
compared to native Asians. For US-born Chinese, Japanese,
Filipino, and Asian Indian men, the annual age-adjusted
incidence rates per 100,000 individuals in the population
were 0.7, 0.8, 1.4, and 2.9, respectively. For native Asians,
the incidence rates were 0.5, 0.5, 0.9, and 1.3, respectively.
US-born Asian women also had higher incidence rates
than native Asian women (0.4 versus 0.3 for Chinese, 0.6
versus 0.2 for Japanese, 1.0 versus 0.4 for Filipino, and 1.5
versus 0.6 for Asian Indians, resp.). Additionally, a young
adult incidence peak occurred only in the US-born Asian
population. According to Glaser and Hsu, consistently low
incidence rates of HL in the Asian population as a whole
suggest genetic resistance, possibly related to HLA type, and
diﬀerences between US and native Asian groups suggest
environmental inﬂuences.
2.5. United Kingdom. Flavell et al. analyzed the eﬀects of
ethnicity and material deprivation on 55 pediatric patients
(under 15 years of age) with HL as well as the inﬂuence of
EBV on HL incidence [31]. Researchers acquired data from
the West Midlands Regional Children’s Tumor Registry in
a multiethnic region of the United Kingdom. The patients
were separated into two ethnic groups based on self-reported
ethnicity: South Asians (of Indian, Pakistani, or Bangladeshi
descent) and non-South Asians (white, black, Hispanic,
Oriental, or of mixed race). Sixty-two percent of all HL cases
were EBV-positive in this study population. EBV-positivity
was strongly associated with ethnic group, with 18 of 19
(95%) South Asian cases being EBV-positive, while only 16
of 36 (44%) non-South Asian cases were EBV positive (P<
.001). Based on these data South Asians had more than a 20-
fold increased risk of EBV-positive HL when compared to
non-South Asians.
Thisgroupalsoinvestigatedtheimpactofmaterialdepri-
vationonHLasdetermined by postal zipcode andmeasured
with the associated Townsend score. Townsend score was
determined by the percent of unemployed residents, percent
of households without cars, percent of households not
owner-occupied, and percent of households with more than
one person per room yielding a possible range of −12 to
+12 (by combining z-scores from −3t o+ 3f o re a c ho ft h e
four factors) [32]. EBV-positivity was associated with higher
deprivation scores (median Townsend score +3.2), whereas
EBV-negativity was associated with lower scores (median
score −0.4). As material deprivation increased (among
Townsend score quartiles), so did the proportion of EBV-
positive HL cases (P = .025). The risk for EBV-positivity
was 7 times higher in the most deprived quartile than the
least. After adjusting for ethnicity, risk was still 3 times
higher. After adjusting for Townsend score, ethnicity was
the only factor independently associated with EBV-positivity
(OR 10.9, 95% CI 1.20–98.6). These data suggest that
ethnicity and material deprivation independently inﬂuence
the development of EBV-associated HL.
3. Risk Factors for HL
3.1. Socioeconomic Status. The population-based studies by
Hjalgrim et al. and Flavell et al. discussed above further
elucidated the role that socioeconomic status (SES) plays in
HL incidence [16, 31]. As noted above, the shift towards
Western lifestyle in Singapore was accompanied by a shift in
HL incidence, and in the UK, patients who had the highest
rates of material deprivation (lowest SES) had a three-
time higher risk for EBV-positive HL. Additional studies
have investigated the eﬀects of socioeconomic factors such
as education, income, and ownership of goods on HL
incidence and survival. In Denmark, Roswall et al. studied
theassociationbetweensocialinequalityandincidenceofHL
and NHL, and leukemia in 8,638 cases in comparison to a
cohort of 3.22 million people, the Denmark population [33].
The investigators used data from individuals born between
1925 and 1973 and diagnosed with HL between 1994 and
2003. Socioeconomic status was determined by means of
a questionnaire inquiring about education level, disposable
income, social class, housing tenure, and the size of dwelling.
Comorbidity was measured with the Charlson comorbidity
index. There was no clear evidence of a relationship between
disease incidence and SES, but there was an association
between comorbidity and overall survival for all three
diseases. Among HL patients (n = 636), age-standardized
relative survival was worst for women with basic education
and men with vocational education. A Brazilian study also
found that higher SES was associated with a better 2-year
survival rate than lower SES (93% versus 79%, P = .01) [34].
3.2. Occupational Exposures. Karunanayake et al. investi-
gated the association between occupational exposures and
risk of HL among 18-to 92-year old Canadian males in
order to better understand the potential epidemiological
underpinnings of HL [19]. Using postal questionnaires and
telephone interviews, researchers acquired occupational and
medical data from 316 cases of HL and 1506 controls.
Exposure was deﬁned as ever having contact with dust,
coal products, printing products, paints, metals, radiation
(divided into nonionizing and ionizing), and other products.
Long-held occupation was deﬁned as having worked for
10 or more years in given occupation. Though there was
no signiﬁcant diﬀerence between HL risk and long-held
occupation (whether accountant, clerk, driver, farmer, engi-
neer, manager, or salesman), exposure to ionizing radiation,
history of certain medical illness, and habit of ever smoking
were associated with risk of HL. Exposure to ionizing
radiation from uranium signiﬁcantly increased risk of HL
(OR 2.58, 95% CI 1.08–6.19). Exposure to ultraviolet light
(OR 0.62, 95% CI 0.4–0.96) and diagnosis of measles (OR
0.7, 95% CI 0.53–0.94) was negatively associated with HL,
whereas a diagnosis of shingles was positively associated
with HL (OR 2.16, 95% CI 1.31–3.56). Subjects with any
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likely to be diagnosed with HL than nonsmokers. These data
are corroborated by studies on exposure to pathogens and
environmental tobacco smoke described below.
3.3. Childhood Environment. An individual’s childhood
social environment may inﬂuence bacterial exposure which,
in turn, can provide clues as to the pathological etiology
of HL. Chang et al. investigated the association between
childhood social environment, namely, exposure to child-
hood pathogens and HL in order to better understand the
disease’s viral etiology [18]. Researchers surveyed 565 HIV-
negative HL cases and 679 controls in Massachusetts and
Connecticut and inquired about level of parental education,
homeownership status, number of siblings, housing density,
birth order, and nursery school/day care attendance. All
questions, with the exception of nursery school attendance,
were answered with the reference age of 8 years old.
For 15 to 54 year olds (ﬁrst incidence peak), HL cases
were more likely than controls to be Jewish rather than
Catholic (OR 2.29, 95% CI 1.26–4.19) or Protestant (OR
1.77, 95% CI 1.01–3.13), to have smoked ≥10 lifetime
packs of cigarettes (OR 1.31, 95% CI 1.03–1.69), to be
less educated (OR 0.82, 95% CI 0.70–0.96), and to have a
family history of hematopoietic cancer (OR 2.06, 95% CI
1.10–3.87). In this same age group, attendance of nursery
school or day care lowered HL risk by 13%. If individuals
attended day care for more than 1 year, the risk of HL
dropped by 36%. These associations were not consistent for
the older age group. Among 55 to 79 year olds, HL risk
was associated with lower childhood socioeconomic status.
Parental education, number of siblings, history of infectious
mononucleosis, and housing density had no signiﬁcant
correlation with HL despite previous ﬁndings in other
studies.
In another study, young adult Hodgkin lymphoma
(YAHL) has been linked to lower levels of interleukin 12
levels and persistence of the T-helper type 2 immature
immune response phenotype [35, 36]. Because YAHL is
associated with a Th-2 skewed immune response [37, 38],
Cozen et al. investigated the relationship between early
microbiological exposures that aﬀect Th-2/Th-1 cytokines
and the incidence of YAHL [20]. Researchers sent 35-page
questionnaires to 188 sets of twins, one with YAHL and
one without (found through a North American twin study
[39]) and asked about early infections, surgical, medical,
and pharmacological history, alcohol and tobacco use, oral
exposure habits such as sucking one’s thumb, education,
and puberty. The reference date for these questions was
ﬁve years before the diagnosis of YAHL as to avoid answers
associated with disease development. Prior appendectomy
(P = .001), eczema (P = .025), and smoking (P = .054)
were associated positively with YAHL incidence, whereas
childhood behaviors associated with oral exposure (thumb-
sucking, toys in mouth, etc.) were inversely associated
with the disease (P = .004). These investigators con-
cluded that early exposure to microbiomes may protect
against onset of YAHL because exposure aﬀects cytokine
balance.
3.4. Personal Health Choices: Exercise, Medication and Alcohol
Use, and Smoking Exercise. Social environment and peer
inﬂuence aﬀect a variety of personal health choices, from
exercise and taking certain medication to smoking cigarettes
and drinking alcohol, that are also associated with HL risk.
Keegan et al. studied height, weight, body mass index, and
strenuous physical activity in association with the risk of
HL in women in 312 cases and 325 controls aged 19 to
79 years, who self-reported these measurements as well
as reproductive factors, exposure to exogenous hormones,
and SES [22]. Strenuous physical activity was deﬁned as
“getting out of breath or working up a sweat” at least
twice a week. In young women, 19 to 44 years of age,
participation in strenuous physical activity for at least one
month before reference period resulted in approximately a
40% reduction in odds of HL. The odds of developing HL
were signiﬁcantly lower with any participation in strenuous
physical activity over the past year in young women (OR
0.58, 95% CI 0.39–0.87) but not older women, 45 to 79 (OR
0.45, 95% CI 0.19–1.06). The relationship between being
overweight, versus normal weight, with respect to HL risk
wassigniﬁcantlydiﬀerentbetweenolderandyoungerwomen
(P = .02). Young women in higher body mass index (BMI)
quartiles had increased risk (ORadj 1.74, 95% CI 1.00–3.02
for4thversus1stquartile),whereasolderwomenwithhigher
BMIs were associated with lower risk (ORadj 0.37, 95% CI
0.11–1.30 for 4th versus 1st quartile). Additionally, taller
height was signiﬁcantly associated with higher risk of HL
(P for trend = .01). Gunnell and Okasha suggest that higher
levels of insulin-like growth factors and/or other growth
hormones found in taller women could potentially be related
to HL tumor growth [40].
3.5. Aspirin Intake. Chang et al. analyzed recent ﬁndings
of an inverse association between routine use of a regular
strength aspirin and HL risk and explored investigations
of selective cyclooxygenase-2 inhibitors and nonaspirin
nonsteroidal anti-inﬂammatory drugs (NSAIDs) in order to
determinewhetherornotaspirintrulydoeshaveaprotective
property against HL [23]. With the aid of Denmark’s
nationwide cancer registries and prescription databases,
researchers identiﬁed 478 cases and 10 controls for each
case with fully disclosed medication histories. Prescription
usersweredeﬁnedassubjectswithtwoormoreprescriptions
of aspirin and/or other NSAIDS. Chang et al. found that
low-dose aspirin use was indeed inversely associated with
HL risk but only among never/rare users of nonaspirin
NSAIDs (OR 0.6, 95% CI 0.3–1.0). There was no signiﬁcant
association between selective cyclooxygenase-2 inhibitors or
other NSAIDs and HL risk.
After ﬁnding that regular use of low-dose aspirin may
reduce risk of HL, Chang et al. performed another study to
examine the biological underpinnings of this phenomenon
[25]. The study investigated polymorphic variation in genes
involved in nuclear factor-κB( N F κB) activation/inhibition,
other inﬂammatory pathways, and aspirin metabolism.
Researchers analyzed 20 SNPs in 7 genes of 473 HL cases
and 373 controls. To determine target genes, the team used6 Advances in Hematology
a candidate-SNP approach and utilized both literature and
database information. HL risk was signiﬁcantly associated
with rs1585215 polymorphisms in NFKB1 (AG versus AA:
OR 2.1, 95% CI 1.5–2.9; GG versus AA: OR 3.5, 95% CI
2.2–5.7, Ptrend = 1.7 × 10
−8) and NFKB1 haplotypes
(Pglobal = 6.0 × 10
−21). Marginally weaker associations
were found between HL risk and SNPs with NFKB1A
and CYP2C9, whereas no association was found with
IKKA/CHUK, PTGS2/COX2, UDP1A6, or LTC4S. Based on
the data, Chang et al. suggests NFKB genetic involvement in
HL pathogenesis.
3.6. Smoking and Environmental Tobacco Smoke. In a French
case-control study, Monnereau et al. investigated the rela-
tionship between cigarette smoking, alcohol consumption,
and risk of lymphoid neoplasm among patients with HL,
non-Hodgkin lymphoma (NHL), multiple myeloma (MM),
and lymphoproliferative syndrome [41]. The research team
sent questionnaires to 824 cases and 752 controls, aged 18
to 75 years, and asked about smoking status, tobacco and
cigarette type, smoking duration, number of cigarettes per
day, lifelong alcohol consumption, and number of drinks
per week. A subject was considered a smoker if he or she
had ever had at least one cigarette per day for more than
6 months, a current smoker if he/she was doing so at the
time of interview. A subject was considered a drinker if
he/she routinely had one drink (beer, wine, aperitif, etc.) per
month. Overall, smoking was not associated with increased
risk of lymphoid neoplasms (OR 0.6, 95% CI 0.4–0.9).
However, average tobacco consumption was inversely related
to lymphoproliferative syndrome and NHL (Ptrend <. 05).
This inverse relationship was especially prevalent between
smoking and hairy cell leukemia (HCL) (OR 0.2, 95% CI
0.1–0.5). There was also an inverse association between
drinking alcohol and HL (OR 0.5, 95% CI 0.3–0.8). These
data could be interpreted to suggest a protective eﬀect of
smoking and alcohol consumption with respect to HL and
NHL; however, fairly broad deﬁnitions for both exposures
were used.
Although this study did address a potential association
between smoking and lymphoma incidence, in separate
studies Briggs et al. and Glaser et al. studied the relationship
between cigarette smoking and HL in men and women,
respectively, in much more depth [21, 24]. They examined
factors such as smoking age onset, duration, intensity, and
even environmental tobacco smoke exposure. To address the
lack of information on the relationship between smoking
and HL in men, Briggs and colleagues investigated whether
a dose-response eﬀect of smoking in relation to risk of HL
exists in the hope of discovering a potential preventable
epidemiological factor for the disease [24]. Using data from
the Selected Cancers Study, researchers conducted 2,104
telephoneinterviewswith308Americanmendiagnosedwith
HL and 1,796 controls, all between the ages of 32 and 60.
Researchers considered smokers as subjects who answered
“yes” to the following question: “Did you ever smoke at least
a 0.5 pack of cigarettes weekly for at least a year?” Smokers
were asked about intensity (packs/day), duration (years),
onsetage,andyearssincequittingifapplicable.Comparedto
never-smokers, current smokers had a signiﬁcantly increased
risk of HL (OR 1.8, 95% CI 1.3–2.9). Furthermore, risk
increased linearly with increase of packs/day (OR 2.5,
95% CI 1.6–4.0), years (OR 2.4, 95% CI 1.5–3.9), and
pack-years (OR 2.7, 95% CI 1.8–4.3) of smoking. Similar
associationswereobservedfornodularsclerosisHLandwere
even more profound for mixed cellularity HL. Additionally,
former smokers, when compared to current smokers, had a
signiﬁcant and linear decrease in risk of HL with increasing
time since having quit. This was true for risk of HL overall
and for HL subtypes.
With the belief that smoking had been considered a risk
factor for HL only among men, Glaser et al. performed
a population-based, case-control study, analyzing the eﬀect
of smoking and household environmental tobacco smoke
(ETS) exposure on women (aged 19 to 79) in the Greater
San Francisco Bay Area [21]. Researchers interviewed 95%
of the 637 subjects (312 diagnosed with HL and 325
randomly selected controls) in person and 5% by telephone,
asking standardized questions about frequency, duration,
and intensity of smoking, if any, and exposure to ETS, age
on onset, and duration of ETS. Because EBV is believed to
play a role in HL etiology, researchers also tested all possible
subjects for tumor-cell EBV and incorporated those ﬁndings
into their results. Among 253 cases compared to 254 control,
aged 19 to 44 years, exposure to ETS in childhood was
associated with a 50% increased risk for HL overall (OR 1.7,
95% CI 0.9–3.4). In 24 cases of EBV-positive HL, current
smoking, greater smoking intensity (P = .05 for current
smokers, P = .02 for ever-smokers) and duration (P = .04
for current smokers, P = .06 for ever-smokers), and ETS
exposure also increased risk. Most smoking characteristics
did not seem to aﬀect HL risk in the other 59 cases and 71
controls, aged 45–79.
4. Impact of Epstein-BarrVirusandHuman
Immunodeﬁciency Virus on HL Incidence
4.1. Epstein-Barr Virus. Because viral infection can damage
DNA and alter cell composition in healthy cells, investigators
have examined the relationships between viral infection, T-
cell function, and the development of HL. For a case to
be determined as EBV-positive HL, EBV nucleic acids and
proteins must be detectable in tumor cells [42]. Although
in North America and Western Europe, 30%–50% of HL
cases are EBV-positive, EBV is detected in a relatively small
proportion of RS/H tumor cells. In parts of Latin America,
Africa, and Asia, however, EBV-positivity in children with
HL approaches 100% [43]. Research led by Dr. Ambinder
suggests that this phenomenon is due to primary infection
of EBV and infectious mononucleosis being a potential
precursor to EBV-associated HL [42].
Although most individuals are EBV seropositive with
antibody responses reﬂecting a prior exposure to EBV,
most individuals have subclinical exposures. In the United
Kingdom, one study followed 500 seronegative college
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to being seropositive. Of those students, 25% developed
infectious mononucleosis [44]. Infectious mononucleosis
was ﬁrst linked with HL in the 1950s, but in the 1980s
viral antigens were found in HL RS/H cells [42]. Oddly
enough, association between infectious mononucleosis and
HL was most prevalent in young adults, although virus
presence in tumor cells was least frequent for this age
group [42]. In a Scandinavian study, researchers found an
association between HL and infectious mononucleosis with
HL tending to occur 2.9 years after occurrence of infectious
mononucleosis [45].
Additionalstudieshaveaidedinourunderstandingofthe
molecular biology of virus-associated HL [46]. EBV-positive
HRS cells express EBNA1, key for viral genome replication,
as well as LMP1 and LMP2a which mimic CD40 receptors
and BCRs, respectively [47, 48]. Additionally, virtually all
HL cases with BCR preventing destructive IgV mutations
are EBV-positive [49]. The Epstein-Barr virus rescues BCR-
mutated GC B cells from apoptosis with LMP2a expression
which leads to EBV-positive HRS cells [48, 50, 51]. In
essence, this ﬁnding suggests that the virus facilitates cancer
cell proliferation. Finally, TNFAIP3 is a tumor suppression
gene that encodes for A20, a tumor suppressing protein.
In EBV-negative HL cases, 70% of patients had destructive
TNFAIP3 mutations. In EBV-positive cases, however, only
12% of patients had TNFAIP3 mutations, and the majority
were missense mutations [52]. These ﬁndings suggest that
EBV has a distinct pathogenic eﬀect on EBV-positive HL
[46]. Crippled immunoglobin genes responsible for the
prevention of apoptosis of cancer cells are not often found
in HL but, when they are, they are almost always found in
EBV-positive HL cases.
In an eﬀort to study EBV-positive HL incidence on an
international scale, Glaser et al. analyzed data from the
US, UK, France, Denmark, Germany, Argentina, and China
[43]. Researchers compared EBV-related HL prevalence in
relation to age of diagnosis, sex, ethnicity, histologic subtype,
country of residence, and clinical stage in 1,546 patients.
EBV prevalence across four age groups (0–14, 15–39, 40–54,
and 55+) was higher among Asians (92.9%, 38.1%, 50.0%,
81.8%) and Hispanics (85.7%, 49.3%, 63.2%, 66.7%) than
among whites (46.2%, 29.6%, 37.6%, 48.3%) and blacks
(16.7%, 13.0%, 33.3%, 20.0%). Almost twice as many males
had EBV-related HL than women (47.7% versus 29.2%).
The highest proportion of EBV-positive HL cases was in
the oldest and youngest age groups. In terms of histologic
subtype, MC had the largest proportion of EBV-positive
HL, and LP had the smallest (70.4% and 16.0%, resp.).
Additionally, patients from less developed countries were
twice as likely to be EBV-positive than those from more
developed countries (63.4% versus 36.0%). EBV-related HL
was most prevalent in Saudi Arabia (87.5%) and least
prevalent in the United Kingdom (30.8%).
Rather than studying EBV inﬂuence on incidence, Kee-
gan et al. assessed the joint eﬀects of EBV with age, sex,
and histologic subtype on survival after HL diagnosis [53].
The study included 922 HL cases among children and adults
in the Greater San Francisco Bay Area who were diagnosed
between 1988 and 1997. For children under 15 years of age,
EBV-positivity was associated with favorable survival (P =
.07; HR (hazard ratio) 0.18, 95% CI = 0.02–1.70). EBV status
did not aﬀect outcome for cases between the ages of 15 and
44, though data suggested a potential protective eﬀect. For
45- to 96-year old patients with the nodular sclerosis subtype
of HL, however, EBV presence nearly doubled risk of death
(P<. 01; HR 2.50, 95% CI 1.50–4.30). Data suggested that
EBV presence played a signiﬁcantly diﬀerent role in survival
between children and older adults with HL.
4.2.HumanImmunodeﬁciencyVirus. Another formof virus-
related HL is human immunodeﬁciency virus- (HIV-)
positive HL. Characteristically, HIV-HL patients present at a
more advanced stagewithassociated extranodal involvement
andB-symptoms.Additionally,themajorityofHIV-HLcases
are of the MC HL subtype, whereas NS HL is most common
for HIV-negative patients [2]. Another distinct feature of
HIV-positive HL is the noncontiguous spread of disease;
some patients even have bone-marrow only presentation.
Biggar et al. found that people with HIV/AIDS were also
more likely than the general population to be diagnosed with
HL. AIDS cases with moderate immunosuppression (225–
249 CD4 cells/μL at onset) were estimated to have a 15-fold
increased risk of HL [54].
Glaser et al. examined the eﬀect of risk factors: EBV
association, incidence rates, and survival rates among HIV-
related HL in San Franciscan men [2]. Researchers analyzed
data on 1,752 patients with HL; 128 of which were HIV-
positive, from the Greater Bay Area Cancer Registry from
1988–1998. Because 95% of HIV-related HL cases were men,
all conclusions are based on data regarding men only. HIV-
positive patientsweremorelikelythanHIV-negativepatients
toexhibitextranodaldisease(67%versus32%),B-symptoms
(77% versus 43%), and advanced Ann Arbor stage III or
IV disease (82% versus 42%). In addition, HIV-positive and
HIV-negative HL estimated survival rate probabilities after
1 year, 2 years, and 5 years of diagnosis were 69% versus
92%, 56% versus 87%, and 38% versus 78%, respectively.
HIV-positive HL patients were more likely to be black than
white (P = .0 2 )a n dm o r el i k e l yt oh a v eM CH L ,L DH L ,
o rC H LN O Ss u b t y p e st h a nh a v eN SH L .T h e3 8H I V -
positive HL patients with NS HL had a signiﬁcantly better
chance of survival than those with other subtypes (P = .03).
Among patients with the HL NOS subtype, risk of HIV-
related disease was higher in blacks than whites (OR 4.40,
95% CI 0.90–21.5). Additionally, EBV was detected in 90%
of the 59 HIV-positive patients, whereas only 32% of the 473
HIV-negative patients were EBV-positive. HIV-positive HL
cases diagnosed after 1996, when highly active antiretroviral
therapies (HAART) came into play, had a marginally better
survival rate than those diagnosed before the HAART era
(P = .07).
4.3. Molecular Biology of Virus-Related HL. Mollaki et al.
studied the risk of Hodgkin lymphoma in relation to
TLR9-1237T>C, TLR9 2848A>G, MYD88-938C>A, and
MYD88 1944C>G gene polymorphisms and haplotypes
[26]. These genetic variants play roles in virus recognition8 Advances in Hematology
and prevention of viral cell proliferation and thus may
be related to viral-mediated diseases. Using tissue samples
from three hospitals in Greece, researchers examined single-
nucleotide polymorphisms (SNPs) from 90 tissue samples
of patients with HL and 92 healthy controls. Polymerase
chain reaction (PCR) was used to amplify DNA fragments
of interest. Researchers determined that carriership for
−1237C and 2848A was associated with increased HL risk
(OR 2.53, 95% CI 1.36–4.71 and OR 6.20, 95% CI 1.30–
28.8, resp.). Between HL cases and controls, estimated
frequencies of TLR9/1237C-2848A and MYD88/938C-
1944G haplotypes were signiﬁcantly diﬀerent (P<. 01),
as were observed TLR9/1237C-TLR9/2848A-MYD88/938C-
MYD88/1944C haplotype diﬀerences between the two
groups (P<. 01). These ﬁndings suggest that TLR9 and
MYD88 haplotypes and TLR polymorphisms are associated
with HL development.
Chetaille et al., members of the French network Groupe
d’Etude des Lymphomas de I’Adulte, aimed to characterize
the microenvironment of CHL [55]. Researchers used 63
CHL tissue samples (10 from children) and proﬁled them
using DNA microarrays. Histiocyte T-cell-rich B-cell lym-
phoma tissue was used as a control because H/TCRBCL and
CHL have similar amounts of reactive cells and macrophages
in the stroma. Unlike CHL, H/TCRBCL tissues exhibited
high expression of PCD1/PD-1, a gene that codes for
lymphocyte inhibitory receptors. Samples also showed that
the presence of EBV was readily distinguishable with gene
signature characteristic of Th1 and antiviral responses (GS9
and GS11, P<. 001; G10, P = .003). Genes overexpressed in
EBV-positive CHL include those involved in innate immune
response (P = .018), immune response (P = .005), and
defense response (P = .007).
Hjalgrimetal.investigatedtheassociationbetweenHLA-
A∗01 and HLA-A∗02 in the setting of infectious mononu-
cleosis (IM) and EBV-related HL to determine whether
or not HLA class-I restricted EBV-speciﬁc cytotoxic T-cell
responses and early immune response to EBV infection in
IM aﬀect pathogenesis of EBV-related HL [56]. Researchers
analyzed 278 EBV-related HL cases and 656 EBV-unrelated
HL controls in a case-series analysis. When comparing
genotypes of the two groups to conﬁrm that EBV-unrelated
HL patients would be appropriate controls, the diﬀerence in
HLA-A∗01 homogeneity was signiﬁcant, reﬂecting a small
number of heterozygotes among EBV-unrelated HL.
Among individuals never diagnosed with IM, there was
nearly tenfold odds variation between HLA-A∗01 and HLA-
A∗02 homozygotes in risk of EBV-related HL (OR 9.45,
95% CI 4.6–19.4). Overall, HLA-A∗01 alleles were associated
with increased risk of EBV-related HL (OR 2.50, 95% CI
1.60–2.88), whereas HLA-A∗02 alleles were associated with
decreased risk (OR 0.70, 95% CI 0.51–0.97). Researchers
also found a positive association between history of IM and
EBV-related HL, though only in patients who lacked both
HLA-A alleles (OR 2.82, 95% CI 1.15–6.90). Additionally,
history of IM was independently associated with risk of EBV-
related HL, though not in the presence of HLA-A∗02 which
appeared to neutralize eﬀect of IM on risk (OR 3.40, 95% CI
1.74–1.66).
5. Conclusions
Epidemiology studies suggest a unique occurrence pattern
of HL. In most Western countries there is a clear bimodal
age incidence with an early peak in young adults followed
by a second peak in older adults, particularly among men.
Similar trends were recently demonstrated in a SEER study
[57]. From our review of the literature, it appears that in the
MiddleEastandpartsofAsiathepeakismorepronouncedin
early childhood. There are also clear clinical and laboratory
diﬀerences across smaller communities in certain areas as
seen in the study conducted in Southern Israel [28].
Our paper suggests that SES is both a potential risk
factor and survival predictor for HL. A socioeconomic
shift towards Western lifestyle was accompanied by an
increased HL incidence in Singapore [15]. Lower SES, on the
other hand, was associated with a worse prognosis. Several
studies conducted in the western world also highlight the
impact of environmental factors that can increase HL risk
[33, 34]. Childhood exposure to pathogens, microbes, and
microbiomes can potentially reduce the risk of HL [18, 20].
Childhood day care attendance and innate behaviors such
as thumb-sucking and putting toys in the mouth have been
inversely associated with HL risk which further suggests
that early pathogen exposure might be beneﬁcial to healthy
development in children [35, 36]. Additionally, there appear
to be marked racial diﬀerences of HL and HL subtypes,
and particular SNPs have been identiﬁed as etiological
factors suggesting that gene-gene and gene-environment
interactions are involved.
Personal health choices can be made that may decrease
individual’s chances of developing HL. Studies have found
that strenuous exercise at least twice a week can decrease the
risk of HL by approximately 40% [22]. Educating children,
adolescents, and adults about the beneﬁts of routine exercise
along with the risks associated with lack of exercise may help
to reduce the incidence of HL in those age groups. Passive
and active smoking is another lifestyle choice that has been
associated with a higher risk of HL [24]. One study found
thatjustbeingexposedtocigarettesmokeasachildincreased
HL risk by approximately 50% [21]. The important ﬁndings
of these possible links to HL allow individuals to opt for
lifestyle modiﬁcations that may reduce the risk of developing
HL and other diseases.
It has been reported that HL may be a rare consequence
of a common infection, with the probability of oncogenesis
increasing with age at the time of infection. Patients with
EBV exposure, which may clinically present itself as IM, are
at a higher risk of HL due to the molecular biology of the
virus [42, 48, 50, 51]. However, relatively few individuals
exposed to EBV or with IM ultimately develop HL. It
has also been documented that HIV-positive HL patients
have more advanced disease at presentation and poorer
survival than those with HIV-negative [2]. The molecular
biology of virus-related HL is still not well understood
but attempts at isolating speciﬁc transcription factors and
genes associated with the disease are underway. Additional
research on the oncogenesis of HL and mitigating genetic
and environmental factors may help clinical researchersAdvances in Hematology 9
expand curative therapies and create preventative strategies
for HL.
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